← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Other antivirals
maraviroc
J05AX09
Forms & Strengths
- Tablets: 25mg, 75mg, 150mg, 300mg
- Oral solution: 20mg/mL
Adult Dosing
- 150mg or 600mg or 300mg twice daily, depending on concomitant medications and resistance testing
- Dose adjustments for renal impairment and hepatic impairment may be required
Pediatric Dosing
- For children and adolescents 2 years and older, dose based on body weight and concomitant medications
- 20mg/kg twice daily, not to exceed the maximum adult dose
Indications
- Treatment of HIV-1 infection in combination with other antiretroviral medications
- Used in treatment-experienced patients with evidence of viral replication
Mechanism of Action
- Selective CCR5 receptor antagonist, blocking HIV-1 entry into host cells
- Does not exhibit significant activity against CXCR4-tropic viruses
Contraindications
- Hypersensitivity to maraviroc or any component of the formulation
- Concomitant use with St. John's Wort
Adverse Reactions
- Gastrointestinal: diarrhea, nausea, vomiting, abdominal pain
- Nervous system: dizziness, fatigue, anxiety, headache
- Hepatotoxicity, orthostatic hypotension, and cardiac events have been reported
Drug Interactions
- Potentiated by CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin), requiring dose reduction
- Weakened by CYP3A4 inducers (e.g., efavirenz, rifampin), requiring dose increase
Curated Content: Needs Vetting Before Put to Clinical Use